Status:

RECRUITING

Venetoclax in Combination with 5 Days Azacitidine in Untreated AML Patients, Not Eligible for Standard Induction Therapy

Lead Sponsor:

University of Leipzig

Collaborating Sponsors:

AbbVie

University Hospital Leipzig, Hematology Diagnostics Laboratory

Conditions:

Acute Myeloid Leukemia (AML)

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

Acute myeloid leukemia (AML): continuous oral Venetoclax (VEN) and 7 days of s.c. Azacitidine (AZA) per 28-day cycle = standard of care for intensive induction therapy ineligible AML patients in Germa...

Detailed Description

Acute myeloid leukemia (AML) is a uniformly fatal disease if untreated. The combination of continuous oral Venetoclax (VEN) and 7 days of s.c. Azacitidine (AZA) per 28-day cycle has recently emerged a...

Eligibility Criteria

Key Inclusion Criteria:

  • Confirmed diagnosis of AML by World Health Organization (WHO) criteria 2016
  • Ineligible for treatment with a standard cytarabine and anthracycline induction regimen due to age or comorbidities
  • Age ≥ 18 years
  • Life expectancy of at least 12 weeks

Key Exclusion Criteria:

  • Prior treatment for AML or myelodysplastic syndrome (MDS) with one of the following:

    • Hypomethylating agent (HMA)
    • Chemotherapeutic agent
    • Chimeric Antigen Receptor (CAR)-T cell therapy
    • Experimental therapies
    • Note: Prior use of hydroxyurea is allowed
  • History of myeloproliferative neoplasm (MPN)

  • Diagnosis of acute promyelocytic leukemia (APL)

  • Presence of favorable-risk karyotype abnormalities: t(15;17), t(8;21), inv(16) or t(16;16)

Key Trial Info

Start Date :

May 17 2023

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

July 1 2025

Estimated Enrollment :

45 Patients enrolled

Trial Details

Trial ID

NCT05833438

Start Date

May 17 2023

End Date

July 1 2025

Last Update

December 9 2024

Active Locations (10)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (10 locations)

1

Helios Klinikum Berlin-Buch Klinik für Hämatologie und Stammzelltransplantation

Berlin, Germany, 13125

2

Klinikum Chemnitz gGmbH Klinik für lnnere Medizin Ill

Chemnitz, Germany, 09116

3

Carl-Thiem-Klinikum Cottbus gGmbH

Cottbus, Germany, 03048

4

Universitatsklinikum Carl Gustav Carus Dresden an der TU Dresden Medizinische Klinik und Poliklinik 1 Bereich Hamatologie

Dresden, Germany, 01307

Venetoclax in Combination with 5 Days Azacitidine in Untreated AML Patients, Not Eligible for Standard Induction Therapy | DecenTrialz